Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing

BACKGROUND: Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC). A better explanation for the variability in the pharmacokinetics (PK) of mitotane, and the optimization and individualization of mitotane treatment, is desirable for patients. OBJECTIVES: This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Anyue, Ettaieb, Madeleine H. T., Swen, Jesse J., van Deun, Liselotte, Kerkhofs, Thomas M. A., van der Straaten, Robert J. H. M., Corssmit, Eleonora P. M., Gelderblom, Hans, Kerstens, Michiel N., Feelders, Richard A., Eekhoff, Marelise, Timmers, Henri J. L. M., D’Avolio, Antonio, Cusato, Jessica, Guchelaar, Henk-Jan, Haak, Harm R., Moes, Dirk Jan A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809008/
https://www.ncbi.nlm.nih.gov/pubmed/32607875
http://dx.doi.org/10.1007/s40262-020-00913-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809008/
https://www.ncbi.nlm.nih.gov/pubmed/32607875
http://dx.doi.org/10.1007/s40262-020-00913-y

Ejemplares similares